|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bhatt JR and Finelli A: Landmarks in the
diagnosis and treatment of renal cell carcinoma. Nat Rev Urol.
11:517–525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
White NM, Khella HW, Grigull J, Adzovic S,
Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA,
et al: miRNA profiling in metastatic renal cell carcinoma reveals a
tumour-suppressor effect for miR-215. Br J Cancer. 105:1741–1749.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Crispen PL, Breau RH, Allmer C, Lohse CM,
Cheville JC, Leibovich BC and Blute ML: Lymph node dissection at
the time of radical nephrectomy for high-risk clear cell renal cell
carcinoma: Indications and recommendations for surgical templates.
Eur Urol. 59:18–23. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lovat F, Valeri N and Croce CM: MicroRNAs
in the pathogenesis of cancer. Semin Oncol. 38:724–733. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang L, Lv L, Liu X, Jiang X, Yin Q, Hao
Y and Xiao L: MiR-223 promotes oral squamous cell carcinoma
proliferation and migration by regulating FBXW7. Cancer Biomark.
24:325–334. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu X, Wang J and Zhang G: miR-4458
regulates cell proliferation and apoptosis through targeting SOCS1
in triple-negative breast cancer. J Cell Biochem. 120:12943–12948.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kanlikilicer P, Bayraktar R, Denizli M,
Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang
X, et al: Exosomal miRNA confers chemo resistance via targeting
Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine.
38:100–112. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu X, Xu T, Hu X, Chen X, Zeng K, Sun L
and Wang S: Elevated circulating miR-182 acts as a diagnostic
biomarker for early colorectal cancer. Cancer Manag Res.
10:857–865. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Emami SS, Nekouian R, Akbari A, Faraji A,
Abbasi V and Agah S: Evaluation of circulating miR-21 and miR-222
as diagnostic biomarkers for gastric cancer. J Cancer Res Ther.
15:115–119. 2019.PubMed/NCBI
|
|
14
|
Sun Y, Yang B, Lin M, Yu H, Chen H and
Zhang Z: Identification of serum miR-30a-5p as a diagnostic and
prognostic biomarker in colorectal cancer. Cancer Biomark.
24:299–305. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Butz H, Nofech-Mozes R, Ding Q, Khella
HWZ, Szabó PM, Jewett M, Finelli A, Lee J, Ordon M, Stewart R, et
al: Exosomal MicroRNAs are diagnostic biomarkers and can mediate
cell-cell communication in renal cell carcinoma. Eur Urol Focus.
2:210–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lou N, Ruan AM, Qiu B, Bao L, Xu YC, Zhao
Y, Sun RL, Zhang ST, Xu GH, Ruan HL, et al: miR-144-3p as a novel
plasma diagnostic biomarker for clear cell renal cell carcinoma.
Urol Oncol. 35:36.e7–e36.e14. 2017. View Article : Google Scholar
|
|
17
|
Chen X, Lou N, Ruan A, Qiu B, Yan Y, Wang
X, Du Q, Ruan H, Han W, Wei H, et al: miR-224/miR-141 ratio as a
novel diagnostic biomarker in renal cell carcinoma. Oncol Lett.
16:1666–1674. 2018.PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dai M, Li L and Qin X: Clinical value of
miRNA-122 in the diagnosis and prognosis of various types of
cancer. Oncol Lett. 17:3919–3929. 2019.PubMed/NCBI
|
|
20
|
Fang H, Liu Y, He Y, Jiang Y, Wei Y, Liu
H, Gong Y and An G: Extracellular vesicle-delivered miR5055p, as a
diagnostic biomarker of early lung adenocarcinoma, inhibits cell
apoptosis by targeting TP53AIP1. Int J Oncol. 45:1821–1832.
2019.
|
|
21
|
Moya L, Meijer J, Schubert S, Matin F and
Batra J: Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289
expression as biomarker for prostate cancer diagnosis. Int J Mol
Sci. 20(pii): E11542019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tan HY, Zheng YB and Liu J: Serum miR-199a
as a potential diagnostic biomarker for detection of colorectal
cancer. Eur Rev Med Pharmacol Sci. 22:8657–8663. 2018.PubMed/NCBI
|
|
23
|
Guo J, Liu C, Wang W, Liu Y, He H, Chen C,
Xiang R and Luo Y: Identification of serum miR-1915-3p and
miR-455-3p as biomarkers for breast cancer. PLoS One.
13:e02007162018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guo SJ, Zeng HX, Huang P, Wang S, Xie CH
and Li SJ: MiR-508-3p inhibits cell invasion and
epithelial-mesenchymal transition by targeting ZEB1 in
triple-negative breast cancer. Eur Rev Med Pharmacol Sci.
22:6379–6385. 2018.PubMed/NCBI
|
|
25
|
Huang T, Kang W, Zhang B, Wu F, Dong Y,
Tong JH, Yang W, Zhou Y, Zhang L, Cheng AS, et al: miR-508-3p
concordantly silences NFKB1 and RELA to inactivate canonical NF-κB
signaling in gastric carcinogenesis. Mol Cancer. 15:92016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhai Q, Zhou L, Zhao C, Wan J, Yu Z, Guo
X, Qin J, Chen J and Lu R: Identification of miR-508-3p and
miR-509-3p that are associated with cell invasion and migration and
involved in the apoptosis of renal cell carcinoma. Biochem Biophys
Res Commun. 419:621–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu FQ, Wang Z, Wang XW, Wang SL, Li XD,
Huang QS and Lin JH: MicroRNA-885-5p promotes osteosarcoma
proliferation and migration by downregulation of cell division
cycle protein 73 homolog expression. Oncol Lett. 17:1565–1572.
2019.PubMed/NCBI
|
|
28
|
Dickerman BA, Torfadottir JE,
Valdimarsdottir UA, Wilson KM, Steingrimsdottir L, Aspelund T,
Batista JL, Fall K, Giovannucci E, Sigurdardottir LG, et al:
Midlife metabolic factors and prostate cancer risk in later life.
Int J Cancer. 142:1166–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tan W, Zhong Z, Wang S, Liu H, Yu H, Tan
R, Hu X, Pan T and Wang Y: The typical metabolic modifiers
conferring improvement in cancer resistance. Curr Med Chem.
24:3698–3710. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rinaldi G, Rossi M and Fendt SM: Metabolic
interactions in cancer: Cellular metabolism at the interface
between the microenvironment, the cancer cell phenotype and the
epigenetic landscape. Wiley Interdiscip Rev Syst Biol Med. Aug
30;20172doi: doi.org/10.1002/wsbm.1397.
|
|
31
|
Zhang J, Ye Y, Chang DW, Lin SH, Huang M,
Tannir NM, Matin S, Karam JA, Wood CG, Chen ZN and Wu X: Global and
targeted miRNA expression profiling in clear cell renal cell
carcinoma tissues potentially links miR-155-5p and miR-210-3p to
both tumorigenesis and recurrence. Am J Pathol. 188:2487–2496.
2018. View Article : Google Scholar : PubMed/NCBI
|
